Key result
Early PCSK9i after acute ischemic stroke reduces early neurological deterioration ~61% vs usual care.
Why the study?
Target LDL-C levels can be difficult to achieve with statins alone after acute ischemic stroke, and early administration of PCSK9 inhibitors may improve clinical outcomes.
Does early administration of PCSK9 inhibitors reduce early neurological deterioration, recurrent stroke/TIA, poor functional outcomes, and mortality in East Asian patients with acute ischemic stroke?
Systematic Review
Does early administration of PCSK9 inhibitors reduce early neurological deterioration, recurrent stroke/TIA, poor functional outcomes, and mortality in East Asian patients with acute ischemic stroke?
Odds Ratio: 0.39 (95% CI 0.26–0.57)
Early initiation of PCSK9 inhibitors within 3 weeks of acute ischemic stroke in East Asian patients is associated with reduced early neurological deterioration, recurrent stroke/TIA, and mortality.
Supports early PCSK9i use in acute ischemic stroke care; extends intensive lipid-lowering benefits to the hyperacute phase.
Background: Dyslipidemia is a modifiable risk factor and predictive biomarker for acute ischemic stroke (AIS) that necessitates early, aggressive lipid-lowering therapy to achieve target low-density lipoprotein cholesterol (LDL-C) levels for primary and secondary prevention. In certain patients, this can be difficult to achieve with statins alone. Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) lipid-lowering agents may improve outcomes when introduced early. This review assessed whether early PCSK9i administration (within 3 weeks of AIS) reduced early neurological deterioration (END), recurrent stroke/transient ischemic attack (TIA), poor functional outcomes, and mortality. Methods: This systematic review and meta-analysis included randomized clinical trials (RCTs) and observational studies. Random-effects meta-analysis and subgroup and sensitivity analyses were used to assess whether effects differed by treatment timing (≤72 vs. >72 h) and study design. Results: Eight studies (three randomized clinical trials) in East Asian cohorts were included. Early PCSK9i initiation significantly reduced END compared with usual care (odds ratio [OR]: 0.39; 95% confidence interval [CI]: 0.26–0.57). Stroke/TIA recurrence and all-cause mortality within 6 months of stroke were also significantly reduced in the PCSK9i group (OR: 0.47; 95% CI: 0.28–0.77 and OR: 0.33; 95% CI: 0.15–0.72, respectively), and early initiation was associated with a greater likelihood of good functional outcomes at 90 days (OR: 2.28; 95% CI: 1.48–3.51). Sensitivity analyses yielded consistent results. Conclusions: Early PCSK9i initiation within 3 weeks of AIS onset was associated with lower rates of END, recurrent stroke/TIA, and mortality, although the certainty of evidence was limited by the small number of included studies and the predominantly observational data. Outcomes did not differ significantly by initiation timing within this period. Large-scale trials in diverse populations are needed to define the optimal initiation window and long-term clinical effects.
No takes yet. Share an insight, caveat, or question.
Alqhtani et al. (2026) conducted a systematic review in acute ischemic stroke. Early PCSK9i administration vs. usual care was evaluated on early neurological deterioration (END) (OR 0.39, 95% CI 0.26-0.57). Early PCSK9i initiation within 3 weeks of acute ischemic stroke significantly reduced early neurological deterioration compared with usual care (OR 0.39; 95% CI 0.26-0.57).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: